Literature DB >> 29975416

Toxicities and outcomes: Do steroids matter?

Douglas B Johnson1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29975416      PMCID: PMC6214744          DOI: 10.1002/cncr.31627

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  22 in total

1.  PD-1 Blockers.

Authors:  Jedd D Wolchok
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

Review 2.  Immune checkpoint inhibitors in challenging populations.

Authors:  Douglas B Johnson; Ryan J Sullivan; Alexander M Menzies
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

3.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

Authors:  Jeffrey S Weber; F Stephen Hodi; Jedd D Wolchok; Suzanne L Topalian; Dirk Schadendorf; James Larkin; Mario Sznol; Georgina V Long; Hewei Li; Ian M Waxman; Joel Jiang; Caroline Robert
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

Review 4.  Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

Authors:  Michael A Postow; Robert Sidlow; Matthew D Hellmann
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

5.  Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.

Authors:  M H Pollack; A Betof; H Dearden; K Rapazzo; I Valentine; A S Brohl; K K Ancell; G V Long; A M Menzies; Z Eroglu; D B Johnson; A N Shoushtari
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

6.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Authors:  Troy Z Horvat; Nelly G Adel; Thu-Oanh Dang; Parisa Momtaz; Michael A Postow; Margaret K Callahan; Richard D Carvajal; Mark A Dickson; Sandra P D'Angelo; Kaitlin M Woo; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

7.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

8.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

Authors:  Douglas B Johnson; Ryan J Sullivan; Patrick A Ott; Matteo S Carlino; Nikhil I Khushalani; Fei Ye; Alexander Guminski; Igor Puzanov; Donald P Lawrence; Elizabeth I Buchbinder; Tejaswi Mudigonda; Kristen Spencer; Carolin Bender; Jenny Lee; Howard L Kaufman; Alexander M Menzies; Jessica C Hassel; Janice M Mehnert; Jeffrey A Sosman; Georgina V Long; Joseph I Clark
Journal:  JAMA Oncol       Date:  2016-02       Impact factor: 31.777

9.  Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.

Authors:  Bridgette A Kanz; Megan H Pollack; Romany Johnpulle; Igor Puzanov; Leora Horn; Alicia Morgans; Jeffrey A Sosman; Suthee Rapisuwon; R Martin Conry; Zeynep Eroglu; Douglas B Johnson
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

10.  Opportunistic infections in patients treated with immunotherapy for cancer.

Authors:  Chrisann Kyi; Matthew D Hellmann; Jedd D Wolchok; Paul B Chapman; Michael A Postow
Journal:  J Immunother Cancer       Date:  2014-06-18       Impact factor: 13.751

View more
  1 in total

1.  Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes.

Authors:  Charline Lafayolle de la Bruyère; Pierre-Jean Souquet; Stéphane Dalle; Pauline Corbaux; Amélie Boespflug; Michaël Duruisseaux; Lize Kiakouama-Maleka; Thibaut Reverdy; Madeleine Maugeais; Gulsum Sahin; Denis Maillet; Julien Péron
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.